Effects of adding celecoxib on brain-derived neurotrophic factor and on the severity of symptoms in patients with bipolar disorder who receive Electroconvulsive therapy

Evaluation and comparison of the effects of celecoxib and placebo on the brain-derived neurotrophic factor and on the severity of mania in patients with bipolar mood disorder in manic phase undergoing electroconvulsive therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201401177202N7

Enrollment

Registered

2014-05-10

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Mood Disorder, Manic Episode. Manic episode

Interventions

Intervention 1: Intervention group: celecoxib 200 mg BID a day before initiation of the elecltoconvulsive therapy until the 6th elecltoconvulsive treatment. Intervention 2: Control group: placebo with

Treatment - Drugs

Intervention group: celecoxib 200 mg BID a day before initiation of the elecltoconvulsive therapy until the 6th elecltoconvulsive treatment

Control group: placebo with similar order as the intervention group and with the same duartion

Eligibility

Sex/Gender

All

Age

17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: meeting the DSM-IV criteria for manic episode of bipolar mood disorder; age between 17 and 65 years; order of receiving electroconvulsive therapy Exclusion criteria: history of allergy to NSAIDs; lactating and pregnant women, cerebrovascular hemorrhage; severe hepatic or renal disease, Patients with rheumatologic disease, organic brain syndrome, concomitant taking of other NSAIDs or corticosteroids, severe medical conditions like cardiovascular disorders, respiratory and gasterointestinal disease, receiving electroconvulsive therapy in the past 2 months, stroke, presence of contraindication of receiving electroconvulsive therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Changes in brain-derived neurotrophic factor. Timepoint: baseline and after sessions 1,3,6 of ECT. Method of measurement: measurment of serum level.	—

Secondary

Measure	Time frame
Severity of mania. Timepoint: baseline and afterECT 3 and 6. Method of measurement: by Young Mania Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Padideh Ghaeli

Faculty of Pharmacy, Tehran University of Medical Scienses

pghaeli@sina.tums.ac.ir+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026